Moderate protective effect of 6-MFA, a microbial metabolite obtained from Aspergillus ochraceus on immunological liver injury in mice

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 22, Issue 1, 1999, Pages 15-25

  Dhuley, Jayant N ^a   Naik, Suresh R ^a  

^a Engineering Research Center   (India)

Author keywords

6 MFA; 6 MPA; Hepatoprotection; Immunological liver injury

Indexed keywords

6 MFA; AMINOTRANSFERASE; ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; COMPLEMENT; DEOXYCHOLIC ACID; IMMUNOGLOBULIN G; LIVER PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS OCHRACEUS; GUINEA PIG; HEMOLYTIC ANEMIA; HEMOLYTIC PLAQUE ASSAY; IMMUNIZATION; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PROPIONIBACTERIUM ACNES; SPLEEN;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, FUNGAL; ASPERGILLUS OCHRACEUS; CYCLOPHOSPHAMIDE; DEOXYCHOLIC ACID; FUNGAL PROTEINS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MICE; MICE, INBRED DBA; RABBITS; RATS; TRANSAMINASES;

ASPERGILLUS OCHRACEUS; BACTERIA (MICROORGANISMS); CAVIA PORCELLUS; CORYNEBACTERIUM PARVUM; FUNGI; ORYCTOLAGUS CUNICULUS; SUS SCROFA;

EID: 0032889701     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0147-9571(98)00021-6     Document Type: Article

References (23)

1. Maheshwari R.K., Gupta B.M. A new antiviral agent designated 6-MFA from Aspergillus flavus. I. Production and assay of 6-MFA against Semliki Forest infection in mice. J Antibiotics. 26:1973;320-327.
2. Maheshwari R.K., Gupta B.M. A new antiviral agent designated 6-MFA from Aspergillus flavus. II. General physico-chemical characterisation of 6-MFA. J Antibiotics. 26:1973;328-334.
3. Maheshwari R.K., Gupta B.M., Ghosh S.N., Gupta N.P. Antiviral agent (6-MFA) from Aspergillus ochraceus: sensitivity of arboviruses in experimentally infected mice. Indian J Med Sci. 67:1978;183-189.
4. Naik S.R., Deshmukh V.K., Raman P.H. Anti-inflammatory activity of 6-MFA, a compound obtained from fungus Aspergillus ochraceus. Jpn J Med Sci Biol. 39:1986;139-149.
5. Maheshwari R.K., Gupta B.M. A new antiviral agent designated 6-MFA from Aspergillus flavus: amplification of anti-Semliki Forest Virus activity of 6-MFA by cycloheximide treatment in mice. J Antibiotics. 26:1973;335-338.
6. Dhuley J.N., Naik S.R. Effect of 6-MFA, an interferon inducer obtained from Aspergillus ochraceus on hepatic mixed function oxidase system in rats. Indian J Exp Biol. 34:1996;1010-1014.
7. Pandya K.P., Ravishankar, Gupta A., Khan W.A., Ray P.K. Modulation of benzene toxicity by an interferon inducer (6-MFA). Toxicology. 36:1986;291-305.
8. Preston H., Wright T.L. Interferon therapy for hepatitis C. Lancet. 348:1996;973-974.
9. Farci P., Mandas A., Coiana A., Lai M.E., Desmet V., Van Eyken P., Gibo Y., Caruso L., Scaccabarozzi S., Criscuolo D., Tyff J.C., Balestrieri A. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 330:1994;88-94.
10. Singh V.K., George C.X., Singh N., Agrawal S.S., Gupta B.M. Combined treatment of mice with Panax ginseng extract and interferon inducer-amplification of host resistance to Semliki Forest Virus. Plant Media. 47:1983;234-235.
11. Almeida J.D., Aterson A.P. Immune complexes in hepatitis. Lancet. 2:1969;938-986.
12. Popper H., Paronetto A.P. Immunologic hepatic injury. Ver Deut Gest Inn Med. 78:1972;790-797.
13. Goldgraber M., Kirsner J. The hypersensitive state and the liver: a critical review. Am J Med Sci. 241:1961;109-124.
14. Mafune N. Purification, characterisation and clinical aspects of a liver specific protein. Hokaiddo J Med Sci. 57:1982;491-501.
15. Nagal H., Takizawa T., Nishiyori T., Koda A. Experimental glomerulo-nephritis in mice as a model for immunopharmacological studies. Jpn J Pharmacol. 32:1982;1117-1121.
16. Reitman S., Frankel S.A. Colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 28:1957;56-63.
17. Mcfarlene I.G., Wojcicka B.M., Zucker G.M., Eddleston A.L.W.F., Willims R. Purification and characterisation of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol. 27:1977;381-390.
18. Ferlunga J., Kaplan A., Allison A.C. Protection of mice against endotoxin-induced liver damage by anti-inflammatory drugs. Agents Action. 9:1979;556-569.
19. Cunningham A.J., Szenberg A. Further improvements in the plaque technique for detecting single antibody forming cells. Immunology. 14:1968;599-600.
20. Fischer H. International symposium on immunological methods of biological standardisation. In: Symp. Series Immunobiol. Standard., vol. 4. Basel: Karger, 1965. p. 221.
21. Aggarwal K.K. Hepatitis update. Indian J Clin Practice: Medinews. 6:1996;20-24.
22. Laker K.F. Liver function tests. Br Med J. 301:1990;250-251.
23. Dhuley JN, Naik SR. Modulation of rifampicin toxicity by 6-MFA, an interferon inducer obtained from fungus Aspergillus ochraceus. Environ Toxicol Pharmacol 1998 (In press).